Literature DB >> 32296499

Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.

Yan Gong1, Ming Yang2, Yongfeng Sun3, Jing Li4, Yongning Lu1, Xingang Li5,6.   

Abstract

Objective: Usage of tacrolimus is complicated by its narrow therapeutic index and wide between- and within-subject pharmacokinetic variability. We aimed to obtain more information regarding the influence of various covariates on the disposition of tacrolimus in the early phase after cardiac transplantation using a population pharmacokinetic method, and provide information for the individualisation of drug dosing in the clinical setting.
Methods: Routine therapeutic drug monitoring concentrations (897 observations) were retrospectively collected from 146 hospitalised patients. One compartment model with first-order absorption (absorption rate constant Ka was fixed as 4.48/hour) was employed to establish the population pharmacokinetic model using a non-linear mixed-effects modelling approach. Various demographic parameters, postoperative day and concomitant medications influencing drug clearance and distribution volume were investigated in this study. Bootstrap and prediction-corrected visual predictive check were employed to validate the final model. With the goal of tacrolimus trough concentrations within the therapeutic window, simulation was performed.
Results: Pharmacokinetic parameter population typical estimates for clearance (CL/F) and apparent distribution volume (V/F) were 14.23 L/hour and 760.80 L, respectively. Postoperative day and co-administration of Wuzhi capsules were identified as important factors affecting CL/F. Total body weight was significantly associated with the V/F. Results of model evaluation indicated a good stable and precise performance of the final model. Based on the simulation results, a simple-touse dosage regimen table to guide clinicians with drug dosing was created.
Conclusion: The final population model could provide information for the individualised dosing of tacrolimus for cardiac transplant recipients. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  body weight; cardiac transplantation; population pharmacokinetics; post-operative day; simulation; tacrolimus; wuzhi capsules

Mesh:

Substances:

Year:  2019        PMID: 32296499      PMCID: PMC7147554          DOI: 10.1136/ejhpharm-2018-001764

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  30 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Tacrolimus Predose Concentration Is Associated With Hypertension in Pediatric Liver Transplant Recipients.

Authors:  Agnieszka Prytula; Kristof Vandekerckhove; Ann Raes; Daniel De Wolf; Jo Dehoorne; Johan Vande Walle; Ruth De Bruyne
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

3.  A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients.

Authors:  Yan-xia Lu; Qing-hong Su; Ke-hua Wu; Yu-peng Ren; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

4.  CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.

Authors:  Violette M G J Gijsen; Ron Hn van Schaik; Laure Elens; Offie P Soldin; Steven J Soldin; Gideon Koren; Saskia N de Wildt
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

5.  Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients.

Authors:  W Jiang; X Wang; X Xu; L Kong
Journal:  Int J Clin Pharmacol Ther       Date:  2010-03       Impact factor: 1.366

6.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

7.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Authors:  Dennis A Hesselink; Ron H N van Schaik; Ilse P van der Heiden; Marloes van der Werf; Peter J H Smak Gregoor; Jan Lindemans; Willem Weimar; Teun van Gelder
Journal:  Clin Pharmacol Ther       Date:  2003-09       Impact factor: 6.875

Review 8.  Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.

Authors:  M A Sikma; E M van Maarseveen; E A van de Graaf; J H Kirkels; M C Verhaar; D W Donker; J Kesecioglu; J Meulenbelt
Journal:  Am J Transplant       Date:  2015-06-04       Impact factor: 8.086

9.  CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

Authors:  Kimberly M Deininger; Anh Vu; Robert L Page; Amrut V Ambardekar; JoAnn Lindenfeld; Christina L Aquilante
Journal:  Clin Transplant       Date:  2016-07-11       Impact factor: 2.863

10.  Status on Heart Transplantation in China.

Authors:  Xing-Jian Hu; Nian-Guo Dong; Jin-Ping Liu; Fei Li; Yong-Feng Sun; Yin Wang
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628

View more
  1 in total

1.  The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.

Authors:  Yan-Nan Zang; Fang Dong; An-Ning Li; Chuan-Yue Wang; Gui-Xin Guo; Qian Wang; Yan-Fang Zhang; Lei Zhang; Jose de Leon; Can-Jun Ruan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03-06       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.